
==== Front
J Gastrointest Oncol
J Gastrointest Oncol
JGO
Journal of Gastrointestinal Oncology
2078-6891
2219-679X
AME Publishing Company

jgo-15-04-2002
10.21037/jgo-24-255
Editorial Commentary
MRTX1133’s promise for treating KRASG12D-mutant pancreatic cancer
Haidar Malak
Jacquemin Patrick
de Duve Institute, Université catholique de Louvain, Brussels, Belgium
Correspondence to: Patrick Jacquemin, PhD. de Duve Institute, Université catholique de Louvain, 75, Avenue Hippocrate, B-1200 Brussels, Belgium. Email: patrick.jacquemin@uclouvain.be.
05 8 2024
31 8 2024
15 4 20022005
10 4 2024
12 6 2024
2024 Journal of Gastrointestinal Oncology. All rights reserved.
2024
Journal of Gastrointestinal Oncology.
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.
Keywords:

Pancreatic ductal adenocarcinoma (PDAC)
KRAS
MRTX1133
Fonds de la Recherche Scientifique (FNRS) FRS-FNRS, BelgiumNos. J.0085.19 and 1.B.213.21F
==== Body
pmcPancreatic cancer, namely pancreatic ductal adenocarcinoma (PDAC), is the seventh leading cause of cancer-related mortality worldwide, with a 5-year survival rate of only 10% (1). Its aggressive nature, along with late-stage diagnosis, typically precludes curative surgical procedures, leaving chemotherapy as the primary therapeutic option, with little survival benefits. Unlike other cancer types, whose fatality rates have dropped due to therapeutic improvements, PDAC mortality remains high due to diagnostic issues, necessitating the urgent development of more effective treatments (2). The genomic landscape of PDAC reveals that oncogenic Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations are the most common driver, accounting for 95% of cases, followed by TP53, CDKN2A, and SMAD4 alterations (3). Notably, the majority of KRAS mutations occur at codon 12, with the G12D mutation dominating. Unfortunately, targeted therapies for these changes remain difficult, prompting research into downstream signaling effectors such as MEK, epidermal growth factor receptor (EGFR), and PI3K inhibitors, but with limited clinical effectiveness in PDAC (1,4).

The oncogenic KRAS mutation is a key driver of uncontrolled cell proliferation and cancer progression in PDAC (5). Historically, targeting mutant KRAS has been difficult due to a lack of suitable molecule inhibitor binding sites. Various screening methodologies, including virtual, high-throughput, and fragment-based approaches, have been used to identify small compounds capable of targeting KRAS (6-9). These strategies target key regions of the KRAS protein involved in its activation and signaling cascade, such as the switch regions (switch I and switch II) critical for guanine nucleotide exchange factors (GEFs) interaction and effector binding. The switch regions (I and II) are key domains in the KRAS protein structure that undergo conformational change when activated (10). When inactive KRAS binds guanosine diphosphate (GDP) to the nucleotide-binding pocket, a GEF catalyzes the exchange of GDP for guanosine triphosphate (GTP) upon activation by extracellular signals. This exchange leads to a change in conformation in the switch region. This conformational change exposes binding sites for downstream effector proteins, allowing KRAS-GTP to interact with and activate signaling pathways essential for cell proliferation, survival, and differentiation (10,11).

Furthermore, targeting the nucleotide-binding site and neighboring surface pockets has been investigated. Studies focusing on generating G12C inhibitors with improved efficacy and drug-like properties led to the discovery of ARS-1620 and AMG510 (sotorasib) as potential therapeutic agents (8,12,13). Both these compounds are covalent inhibitors that form irreversible bonds with the cysteine residue at position 12 of KRASG12C, locking the protein in its inactive GDP-bound state and preventing downstream signaling activation. ARS-1620 suppressed RAS-GTP and downstream protein phosphorylation in G12C-mutant lung cancer cells in a dose-dependent and selective manner (13). This compound has great potency and selectivity for mutant KRAS alleles, resulting in growth inhibition and apoptosis in mutant cells. ARS-1620’s selectivity for the G12C allele was supported by a variety of tests. In a phase 1/2 trial, patients with advanced KRAS G12C-mutant solid tumors were treated with AMG 510, which resulted in stable disease and tumor shrinkage in certain cases. Patients with highly pretreated advanced KRASG12C colorectal cancer (CRC) showed an objective response rate of 7.1% and a disease control rate of 73.8%. Tumor shrinkage was reported in a large proportion of patients at all dose levels (12). The Food and Drug Administration (FDA) granted AMG 510 fast-track status for treating individuals with previously treated metastatic non-small cell lung cancer (NSCLC) carrying a KRASG12C mutation.

Building on this achievement, MRTX1133, a noncovalent and selective small molecule inhibitor capable of binding the inactive state of the KRASG12D protein was developed (14). MRTX1133 offers a different approach, specifically targeting the KRASG12D mutation. It binds reversibly to the KRASG12D protein, stabilizing it in the inactive GDP-bound conformation. This non-covalent interaction is significant because it avoids the permanent modification of the protein, potentially reducing the likelihood of resistance mechanisms that can arise with covalent inhibitors. Preclinical investigations indicate that this molecule has the potential to revolutionize PDAC treatment, especially considering that approximately 93% of PDACs harbor KRAS mutations, with G12D (~42% of cases) and G12V (~32% of cases) being the most common mutations. In this context, Wei et al. reviewed recent studies on the development and therapeutic implications of MRTX1133 in PDAC, focusing on its powerful inhibition of KRAS pathway signaling (15). Furthermore, they highlighted its high selectivity for KRASG12D mutations and efficacy in PDAC treatment, as demonstrated in both in vivo and patient-derived xenograft models (16). The study assessed MRTX1133’s efficiency in addressing alternative KRAS mutations. MRTX1133 binds to KRASG12D with strong affinity and selectivity when compared to KRASWT. It substantially inhibited activated KRASG12D and significantly reduced cell viability in KRASG12D-mutant cell lines. In PDAC models, MRTX1133 inhibited KRAS-mediated signal transduction and tumor regression in a dose-dependent manner. Co-targeting KRASG12D with other pathways, including EGFR or PI3Kα, increased anti-tumor effectiveness. These findings indicate that KRASG12D-mutant cancers can be specifically targeted with high-affinity small molecules and rely on mutant KRAS for growth and survival (16).

PDAC is distinguished by a desmoplastic reaction that alters the tumor microenvironment (TME), resulting in decreased vascularization, increased immune cell infiltration, and poor medication delivery, all of which contribute to disease progression and resistance (17). Thus, targeting the TME appears to be a potential strategy for increasing the efficacy of combination medicines in PDAC treatment. In the current article, Wei et al. highlighted the relevance of immune monitoring in pancreatic cancer, as well as the challenges posed by an immunosuppressive TME, which is responsible for the poor efficacy of immune treatments in the treatment of PDAC. They also shed insight on studies that showed MRTX1133’s immune-mediated anti-cancer activity, particularly when combined with immune checkpoint inhibitor therapy targeting CTLA-4 and PD-1 (18). MRTX1133’s impact on early and advanced PDAC, as well as the TME, was investigated using 16 distinct models of KRASG12D-driven PDAC. MRTX1133 was found to reverse early PDAC growth, enhance intratumoral CD8+ effector T cells, diminish myeloid infiltration, and modify cancer-associated fibroblasts (18). Furthermore, MRTX1133 caused regression of both established precursor lesions [pancreatic intraepithelial neoplasia (PanINs)] and advanced PDAC, with the latter requiring CD8+ T cells for regression. Combining immune checkpoint blockade (ICB) with MRTX1133 eliminated PDAC and increased overall survival. In addition, inhibiting KRASG12D mutations in advanced PDAC and human patient-derived organoids increased FAS expression in cancer cells and promoted CD8+ T cell killing (18). Based on these findings, a synergistic combination of MRTX1133 and ICB in clinical studies has been proposed.

Despite MRTX1133’s prominent efficacy in developing KRAS-targeted PDAC treatment, its application faces major challenges. Wei et al. addressed these issues, including the development of resistance to MRTX1133, because not all PDAC cells with KRASG12D mutations respond to treatment, and cancer cells can develop resistance over time (15). Treatment with MRTX1133 has been shown to increase EGFR and HER2 expression and phosphorylation, implying that blocking ERBB signaling may boost MRTX1133’s anticancer action (19). Afatinib, a pan-ERBB inhibitor, worked in combination with MRTX1133 in vitro and maintained potency against cancer cells resistant to MRTX1133. In orthotopic PDAC mice models, the combination of MRTX1133 and afatinib reduced tumor size and improved survival rates. These findings highlight the potential synergistic effect of addressing both the ERBB and KRAS signaling pathways to overcome acquired resistance in patients with KRAS-mutant pancreatic cancer (19).

Furthermore, MRTX1133 treatment has been demonstrated to cause reversible growth arrest in KRASG12D-mutant CRC cells while partially reactivating RAS effector signaling (20). A synthetic lethality screen revealed that MRTX1133 inhibits the EGFR and is synthetically deadly. MRTX1133 inhibits ERRFI1 expression, a negative regulator of EGFR, resulting in EGFR feedback activation. Surprisingly, wild-type RAS isoforms (H-RAS and N-RAS), rather than oncogenic K-RAS, influence downstream signaling upon EGFR activation, resulting in RAS effector signaling rebound and reduced MRTX1133 effectiveness. However, inhibiting activated EGFR using therapeutically used antibodies or kinase inhibitors improves MRTX1133 monotherapy efficacy, causing regression of KRASG12D-mutant CRC organoids and cell line-derived xenografts. This study highlights EGFR feedback activation as a critical biological event limiting the effectiveness of KRASG12D inhibitors and proposes a viable combination therapy for individuals with KRASG12D-mutant CRC (20).

Other genetic changes, such as the inactivation of tumor suppressors and the activation of mutations in the p110α subunit of PI3K (PIK3CA), contribute to PDAC’s aggressiveness and resistance. Mouse models with constitutively active PI3K in the pancreas showed an increased number of pre-neoplastic lesions and invasive pancreatic cancer (21). Dual PI3K/mTOR inhibition has demonstrated great efficacy, particularly in tumors with elevated PI3K pathway activation, as well as a reduction in enhanced ERK1/2 signaling, which is typical in human pancreatic malignancies. Thus, addressing the PI3K pathway with inhibitors shows promise for patients with PIK3CA mutant pancreatic tumors (21). In light of these findings, Wei et al. proposed establishing MRTX1133-resistant cancer cell lines, testing combination therapy, and developing more effective KRAS-mutant inhibitors (15). Importantly, some studies have started looking for alternatives to overcome the resistance to MRTX1133 treatment that could emerge in pancreatic cancer. It was demonstrated that MRTX1133-resistant PDAC cells were sensitive to KPT-8602 (inhibitor of the nuclear transport exportin I), and the combination enhanced the inhibition of KRAS downstream pathways. In a xenograft model, the combination significantly reduced tumor burden in mice (22). Another study tested the combination of MRTX1719 (an MTA-cooperative PRMT5 inhibitor) with either adagrasib or MRTX1133, showing enhanced anti-tumor activity in CDX models with both KRAS mutations and MTAP deletion. For instance, in the pancreatic KP4 model, combining MRTX1719 with MRTX1133 prevented adaptive resistance observed with monotherapy and led to sustained tumor regression. Mechanistically, the combination strongly inhibited both PRMT5 and RAS signaling pathways, enhancing the inhibition of RB-1 phosphorylation (23).

Finally, this publication provides a detailed assessment of MRTX1133’s potential for developing KRAS-targeted PDAC therapy and the problems involved with its implementation. Additional research is needed to overcome constraints that may limit its efficacy and to evaluate the implications of combining MRTX1133 with other medications for better treatment outcomes. The development of more effective and broad-spectrum KRAS-mutant inhibitors is also crucial for enhancing the efficacy of KRAS-targeted treatments in PDAC.

Supplementary

The article’s supplementary files as

10.21037/jgo-24-255

Acknowledgments

Funding: This research was funded by Fonds de la Recherche Scientifique (FNRS) FRS-FNRS, Belgium (Nos. J.0085.19 and 1.B.213.21F ).

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Peer Review File
Available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-255/prf

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Gastrointestinal Oncology. The article has undergone external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-255/coif). M.H. is a Research Assistant at the Fonds de la Recherche Scientifique (FNRS) FRS-FNRS. P.J. is a Research Director at FRS-FNRS. The authors have no other conflicts of interest to declare.
==== Refs
References

1 Halbrook CJ Lyssiotis CA Pasca di Magliano M Pancreatic cancer: Advances and challenges. Cell 2023;186 :1729-54. 10.1016/j.cell.2023.02.014 37059070
2 Ushio J Kanno A Ikeda E Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics (Basel) 2021;11 :562. 10.3390/diagnostics11030562 33804776
3 Bailey P Chang DK Nones K Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531 :47-52. 10.1038/nature16965 26909576
4 Aung KL McWhirter E Welch S A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2022;13 :3216-26. 10.21037/jgo-22-86 36636049
5 Linehan A O'Reilly M McDermott R Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Front Med (Lausanne) 2024;11 :1369136. 10.3389/fmed.2024.1369136 38576709
6 Cox AD Fesik SW Kimmelman AC Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov 2014;13 :828-51. 10.1038/nrd4389 25323927
7 Leshchiner ES Parkhitko A Bird GH Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc Natl Acad Sci U S A 2015;112 :1761-6. 10.1073/pnas.1413185112 25624485
8 Ostrem JM Peters U Sos ML K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503 :548-51. 10.1038/nature12796 24256730
9 Welsch ME Kaplan A Chambers JM Multivalent Small-Molecule Pan-RAS Inhibitors. Cell 2017;168 :878-889.e29. 10.1016/j.cell.2017.02.006 28235199
10 Vigil D Cherfils J Rossman KL Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010;10 :842-57. 10.1038/nrc2960 21102635
11 Kolch W Berta D Rosta E. Dynamic regulation of RAS and RAS signaling. Biochem J 2023;480 :1-23. 10.1042/BCJ20220234 36607281
12 Hong DS Fakih MG Strickler JH KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020;383 :1207-17. 10.1056/NEJMoa1917239 32955176
13 Janes MR Zhang J Li LS Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell 2018;172 :578-589.e17. 10.1016/j.cell.2018.01.006 29373830
14 Wang X Allen S Blake JF Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor. J Med Chem 2022;65 :3123-33. 10.1021/acs.jmedchem.1c01688 34889605
15 Wei D Wang L Zuo X A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res 2024;30 :655-62. 10.1158/1078-0432.CCR-23-2098 37831007
16 Hallin J Bowcut V Calinisan A Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med 2022;28 :2171-82. 10.1038/s41591-022-02007-7 36216931
17 Ho WJ Jaffee EM Zheng L . The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol 2020;17 :527-40. 10.1038/s41571-020-0363-5 32398706
18 Mahadevan KK McAndrews KM LeBleu VS KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell 2023;41 :1606-1620.e8. 10.1016/j.ccell.2023.07.002 37625401
19 Gulay KCM Zhang X Pantazopoulou V Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Cancer Res 2023;83 :3001-12. 10.1158/0008-5472.CAN-23-1313 37378556
20 Feng J Hu Z Xia X Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer. Oncogene 2023;42 :1620-33. 10.1038/s41388-023-02676-9 37020035
21 Payne SN Maher ME Tran NH PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis 2015;4 :e169. 10.1038/oncsis.2015.28 26436951
22 Khan YH Aboukameel A Uddin MH Abstract B077: KRASG12D inhibitor MRTX1133 synergizes with the next generation nuclear transport protein inhibitor eltanexor resulting in enhanced antitumor activity against pancreatic ductal adenocarcinoma. Cancer Res 2024:84 :B077. 10.1158/1538-7445.PANCA2023-B077
23 Engstrom LD Aranda R Waters L MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer Discov 2023;13 :2412-31. 10.1158/2159-8290.CD-23-0669 37552839
